Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements.

The British journal of surgery·2026

Same author

Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.

The Lancet. Oncology·2026

Same author

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Scientific reports·2026

Same author

Reconsidering the terminology of "early" and "advanced" gastric cancer: toward a harmonized global lexicon.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026

Same author

Response to van Rossum et al.: contextualizing ESOPEC in the evolving landscape of esophageal adenocarcinoma therapy.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026

Search research articles

Related Experiment Video

Updated: Jul 12, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract.

Gustavo B Baretton¹, Florian Lordick²,

¹Institute for Pathology, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.

Journal of Cancer Research and Clinical Oncology

|October 24, 2023

Summary

Evaluating programmed cell death-ligand 1 (PD-L1) expression is crucial for guiding immuno-oncology treatments in upper gastrointestinal cancers. This study provides recommendations for standardized PD-L1 testing and interpretation in clinical diagnostics.

Keywords:

Esophageal squamous cell carcinoma Gastric adenocarcinoma Gastroesophageal junction adenocarcinoma Immune checkpoint inhibitor PD-L1 testing Predictive biomarkers

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Jul 12, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Immunology
Pathology

Background:

Increasing complexity in treating esophageal, gastroesophageal junction, and stomach cancers due to immuno-oncology advancements.
Treatment decisions for PD-1 inhibitors often rely on programmed cell death-ligand 1 (PD-L1) expression, necessitating accurate biomarker evaluation.

Purpose of the Study:

To address challenges in the clinical diagnostic work of PD-L1 testing for upper gastrointestinal carcinomas.
To develop recommendations for standardized implementation, quality assurance, and interpretation of PD-L1 testing.

Main Methods:

An interdisciplinary expert group convened to discuss practical questions in pathological and clinical practice.
Focus on crucial aspects including starting material, quality-assured testing, and interpretation of pathological findings.

Main Results:

Identified challenges in the daily clinical diagnostic work related to PD-L1 testing due to tumor heterogeneity.
Developed expert recommendations for structured reporting of PD-L1 expression in upper gastrointestinal cancers.

Conclusions:

Standardized and reliable PD-L1 testing is essential for effective immuno-oncology treatment stratification in upper gastrointestinal cancers.
Recommendations aim to improve consistency and accuracy in pathological assessment, aiding clinical decision-making.